Lobe Sciences Advances L-130 for Chronic Cluster Headache and S-100 for Sickle Cell Disease, Targets Late 2026 IND Filing
核心洞察
Lobe Sciences is advancing L-130, a patented stabilized psilocin new chemical entity, initially targeting chronic cluster headache (搜索) with an IND filing planned for late 2026.
A first-in-human safety study of L-130 completed in 2024 reported no serious adverse events and no hallucinations at the study dose.
The company's S-100 (搜索) program for sickle cell disease (搜索), a proprietary fatty acid triglyceride formulation, is targeting a Phase 2 study initiation in the first half of 2027.
Lobe Sciences Ltd. is advancing two distinct therapeutic programs through its subsidiaries, with a lead CNS candidate targeting chronic cluster headache (搜索) and an early-stage program for sickle cell disease (搜索) progressing toward clinical milestones. The company, through its subsidiary Cynaptec Pharmaceuticals, is developing L-130 (psilocin mucate) (搜索), a patented, highly bioavailable, orally administered new chemical entity (NCE) designed as a stabilized form of psilocin, the active metabolite of psilocybin.
The company is also advancing S-100 (搜索), a lipid-based therapeutic candidate for sickle cell disease (搜索), through its wholly owned subsidiary Applied Lipid Therapeutics LLC (搜索). Both programs reflect the company's strategy of disciplined milestone execution across its subsidiary portfolio.
L-130: A Stabilized Psilocin Approach for Chronic Cluster Headache (搜索)
L-130 is designed to provide enhanced stability, improved bioavailability, and more consistent circulating levels of psilocin, supporting reliable systemic exposure relative to traditional psilocybin-based approaches. The program is initially being developed for the treatment of chronic cluster headache (搜索), a severe neurological condition with limited treatment options, and is advancing in alignment with guidance received from the U.S. Food and Drug Administration following pre-IND interactions.
A first-in-human safety study was completed in 2024 and reported no serious adverse events and no hallucinations at the study dose. The company is conducting additional preclinical work in support of an Investigational New Drug (IND) filing targeted for late 2026, with additional Phase 1 and Phase 2a proof-of-concept studies to follow.
Beyond chronic cluster headache (搜索), Lobe Sciences is evaluating additional indications for L-130, including generalized anxiety disorder (搜索) and substance use disorder (搜索), based on promising preclinical data. Cynaptec Pharmaceuticals holds multiple issued U.S. and international patents protecting the stabilized crystalline form of psilocin. Lobe Sciences holds a 64% ownership interest in Cynaptec.
S-100 (搜索): Targeting Sickle Cell Disease (搜索) with a Lipid-Based Platform
S-100 (搜索) is an early-stage therapeutic candidate for sickle cell disease (搜索) being developed through Applied Lipid Therapeutics LLC (搜索). It is designed to address underlying disease mechanisms using a lipid-based delivery platform, consisting of a unique blend of triglyceride esters of docosahexaenoic acid (DHA) (搜索) and eicosapentaenoic acid (EPA) (搜索), combined with a patented absorption-enhancing excipient system to improve bioavailability.
The company is advancing chemistry, manufacturing, and controls (CMC) activities to support production of clinical supply for a planned Phase 2a study. European and United Kingdom patents have been issued for S-100 (搜索), and a U.S. orphan drug designation application is currently under FDA review. The company is targeting initiation of a Phase 2 study in the first half of 2027, following completion of formulation and required regulatory preparatory work.
Financial Position and Corporate Developments
Subsequent to the second quarter of 2026, Lobe Sciences completed a non-brokered private placement, issuing 14,615,384 common shares at $0.065 per share for gross proceeds of approximately $950,000. The financing was completed at pricing reflective of prevailing market conditions and provides additional working capital to support the continued advancement of the company's development programs.
The company's third subsidiary, Alera Pharmaceuticals (搜索), is currently evaluating potential acquisitions of a new pharmaceutical program, consistent with the company's strategy of expanding its subsidiary portfolio.
Dr. Frederick D. Sancilio, Chief Executive Officer of Lobe Sciences, continues to lead the company's efforts to strengthen its corporate infrastructure and advance its core development programs through disciplined milestone execution.